GEHC

GE HealthCare announced five new global clinical collaborations to evaluate its StarGuide GX digital SPECT/CT system, a next-generation nuclear medicine imaging platform using advanced detector technology and NVIDIA computing. The system has received CE Mark approval in Europe but awaits FDA clearance in the US. The collaborations with leading institutions aim to advance quantitative imaging, dynamic imaging, and theranostics applications, supporting GEHC's competitive positioning in the growing precision oncology market.

The Law Offices of Frank R. Cruz is investigating GE HealthCare Technologies for potential federal securities law violations. The investigation follows the company's April 2026 earnings report, which revealed a PDx supplier recall that impacted profit performance and margins, leading to reduced full-year EPS guidance and a 13.2% stock price decline. The company's CFO also stepped down in July 2026.

In a comparison of two medical products stocks, GE HealthCare Technologies (GEHC) emerges as the more attractive option for value investors compared to Stryker (SYK). GEHC has a higher Zacks Rank (#2 Buy vs #3 Hold), lower forward P/E ratio (12.97 vs 18.23), and a lower P/B ratio (2.63 vs 4.36), earning a Value grade of B compared to SYK's C grade.

GE HealthCare Technologies (GEHC) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company is expected to earn $4.93 per share for fiscal year 2026, with analysts steadily raising estimates over the past three months. The upgrade positions GEHC in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation driven by improving business fundamentals.

The global computed tomography market is experiencing significant innovation driven by photon-counting technology, AI integration, and mobile imaging systems. Despite market maturity and coverage challenges, these advances are expanding access to CT imaging across hospitals, clinics, and emerging care settings including veterinary and dental applications. Key manufacturers are competing on slice count, AI capabilities, and spectral imaging technologies.

Vaso Corporation (VASO) has gained 149% over the past year, significantly outperforming its industry peers and the S&P 500. The healthcare-focused company reported improved Q2 2026 results with higher revenues and profitability, driven by growth in professional sales services and medical device segments.

Following the divestiture of its IT services business, VASO is streamlining operations and strengthening its focus on healthcare. However, the company faces challenges including heavy dependence on GE HealthCare and ongoing profitability pressures in its proprietary medical products division.

Intuitive Surgical (ISRG) is expected to report Q3 2026 earnings on October 20 with EPS projected at $2.61 (up 8.75%) and revenue growth of 15% to $2.88B. While the company benefits from international procedure growth and strong da Vinci 5 demand, it faces headwinds from moderating U.S. procedure growth, China pricing pressures, and higher costs. The stock trades at a premium valuation of 35.87X forward P/E, leaving limited room for disappointment.

The global digital X-ray market is projected to grow from $5.79 billion in 2025 to $9.90 billion by 2036, expanding at a 5.09% CAGR. Growth is driven by the transition from analog to digital systems, adoption of mobile and retrofit solutions, AI-enabled workflows, and detector innovations.

North America leads the market, while Asia-Pacific presents significant expansion opportunities. Key challenges include workforce shortages and integration complexity.

The global mobile X-ray systems market is projected to grow from $2.06 billion in 2025 to $4.00 billion by 2036, with a CAGR of 6.30%. Growth is driven by rising chronic disease prevalence, increasing hospitalization rates, and demand for point-of-care imaging.

Digital systems dominate with 91.57% market share, while handheld/ultra-portable systems are the fastest-growing segment. Asia-Pacific leads regional growth at 7.43% CAGR, followed by North America and Europe.

The global mobile C-arm market is projected to grow from $2.09 billion in 2025 to $3.71 billion by 2036, expanding at a 5.35% CAGR. Growth is driven by rising adoption of minimally invasive surgery, AI integration, 3D imaging, and aging populations.

North America leads the market, with hospitals as the primary end-users. Key challenges include high capital costs and shortage of skilled professionals, while advanced storage and archiving capabilities present significant growth opportunities.